Jupiter Neurosciences, Inc. (JUNS) Latest Company News

Aug 27, 2026, 00:00 UTC
Jupiter Neurosciences, Inc. forgave accrued and unpaid compensation owed to its executives Christer Rosén, Alison Silva, Marshall Hayward, and Alexander Rosén, effective August 26, 2026.
Aug 21, 2026, 16:20 UTC
Jupiter Neurosciences priced a $2.0 million registered direct offering of 307,692 shares of common stock on August 21, 2026.
Source:
- globenewswire.com
- thefly.com
Jul 28, 2026, 00:00 UTC
Jupiter Neurosciences, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., issuing 11,470,000 shares of common stock for approximately $3.6 million in proceeds, with a maximum commitment of up to $20 million.
Jul 21, 2026, 11:13 UTC
Jupiter Neurosciences signs a definitive agreement to acquire exclusive U.S. rights to ALA-002 in a transaction valued at up to $100 million.
Source:
- globenewswire.com
Jul 21, 2026, 00:00 UTC
Jupiter Neurosciences issued shares of its common stock as partial upfront consideration for a license agreement with PharmAla, relying on a private placement exemption under Section 4(a)(2) and Rule 506(b).
Jul 7, 2026, 12:58 UTC
Jupiter Neurosciences appointed Dr. Tomas J. Philipson to its board of directors.
Source:
- globenewswire.com
Jun 22, 2026, 00:00 UTC
Allison W. Brady resigned from the Board of Directors, Audit Committee and Compensation Committee of Jupiter Neurosciences, Inc., effective June 17, 2026.
Jun 5, 2026, 00:00 UTC
Jupiter Neurosciences, Inc. appointed Alison Silva as Chief Operating Officer and President, effective June 5, 2026, with an option grant to purchase up to 600,000 shares of common stock under the 2025 Equity Incentive Plan vesting over three years from September 2, 2026.

JUNS

Jupiter Neurosciences, Inc. forgave accrued and unpaid compensation owed to its executives Christer Rosén, Alison Silva, Marshall Hayward, and Alexander Rosén, effective August 26, 2026.

Jupiter Neurosciences priced a $2.0 million registered direct offering of 307,692 shares of common stock on August 21, 2026.

Jupiter Neurosciences, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, Ltd., issuing 11,470,000 shares of common stock for approximately $3.6 million in proceeds, with a maximum commitment of up to $20 million.

Jupiter Neurosciences signs a definitive agreement to acquire exclusive U.S. rights to ALA-002 in a transaction valued at up to $100 million.

Jupiter Neurosciences issued shares of its common stock as partial upfront consideration for a license agreement with PharmAla, relying on a private placement exemption under Section 4(a)(2) and Rule 506(b).

Jupiter Neurosciences appointed Dr. Tomas J. Philipson to its board of directors.

Allison W. Brady resigned from the Board of Directors, Audit Committee and Compensation Committee of Jupiter Neurosciences, Inc., effective June 17, 2026.

Jupiter Neurosciences, Inc. appointed Alison Silva as Chief Operating Officer and President, effective June 5, 2026, with an option grant to purchase up to 600,000 shares of common stock under the 2025 Equity Incentive Plan vesting over three years from September 2, 2026.